Featured Research

from universities, journals, and other organizations

New Tumor Inhibitor For Treatment Of Hereditary Breast Cancer Shows Promising Results In Mouse Model

Date:
November 2, 2008
Source:
Netherlands Cancer Institute
Summary:
Researchers used the novel inhibitor AZD2281 to target breast cancer, in which the BRCA1-gene plays a role, in a genetically engineered mouse model. Treatment resulted in tumor regression and a strong increase in survival without signs of toxicity. The inhibitor, which recently entered trials in human cancer patients, thus seems to have therapeutic potential for BRCA-defective tumors.

Researchers of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital used the novel inhibitor AZD2281 to target breast cancer, in which the BRCA1-gene plays a role, in a genetically engineered mouse model. Treatment resulted in tumor regression and a strong increase in survival without signs of toxicity. The inhibitor, which recently entered trials in human cancer patients, thus seems to have therapeutic potential for BRCA-defective tumors.

Resistance

Long-term treatment with AZD2281 in the mouse model did result in the development of drug resistance. This could however be reversed by coadministration of an other type of inhibitor, tariquidar. Furthermore, the researchers studied the effect of combined treatment with AZD2281 and cisplatin or carboplatin. This increased the recurrence-free and overall survival, suggesting that AZD2281 potentiates the effect of these DNA-damaging agents.

Model

The researchers previously developed the mouse model to study BRCA1-associated breast tumors. BRCA1 defects are often observed in so called triple-negative tumors. No targeted therapy exists yet for this type of breast cancer, which account for about 15% of all breast tumors. The researchers now use the mouse model for preclinical evaluation of potential therapeutics that target tumors with BRCA1 defects and that might be useful for treatment of triple-negative cancers.

The results with AZD2281 show that the mouse model is not only useful for the investigation of the efficacy and toxicity of chemical compounds. Also the development, prevention and circumvention of drug resistance can be tested in the model. Hence, intervention studies in the mouse model may help to predict the basis of resistance to novel therapeutics well in advance of the human experience.

Ultimately, this may improve the clinical success rate for novel anticancer drugs.


Story Source:

The above story is based on materials provided by Netherlands Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O. H. Nygren, Serge A. L. Zander, Patrick W. B. Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau, Robert Boulter, Aaron Cranston, Mark J. O'Connor, Niall M. B. Martin, Piet Borst, and Jos Jonkers. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. PNAS Online Early Edition, October 29, 2008

Cite This Page:

Netherlands Cancer Institute. "New Tumor Inhibitor For Treatment Of Hereditary Breast Cancer Shows Promising Results In Mouse Model." ScienceDaily. ScienceDaily, 2 November 2008. <www.sciencedaily.com/releases/2008/10/081030075651.htm>.
Netherlands Cancer Institute. (2008, November 2). New Tumor Inhibitor For Treatment Of Hereditary Breast Cancer Shows Promising Results In Mouse Model. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2008/10/081030075651.htm
Netherlands Cancer Institute. "New Tumor Inhibitor For Treatment Of Hereditary Breast Cancer Shows Promising Results In Mouse Model." ScienceDaily. www.sciencedaily.com/releases/2008/10/081030075651.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins